Abstract It has been reported that oxidative stress may play a role in the pathogenesis of dementia of the Alzheimer type (AD) and the cerebral ischemia which causes vascular dementia (VD). We measured malondialdehyde (MDA) levels and superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GR) activities in blood samples from patients with AD and VD and in healthy non-demented controls (CTR) which similar ages to the patients, in order to evaluate the degree of oxidative stress in patients with AD and VD. A sample of 150 subjects consisting of 50 patients with AD; 50 patients with VD and 50 CTR, aged from 65 to 85 years on, was analyzed. Most of the changes observed were in SOD activity and MDA levels. Catalase activity were least affected. Significant differences were observed in SOD and GR activity between males and females in CRT and in patients with AD, but not in VD. We have found a decrease in antioxidant enzymes activities (SOD, CAT, GPx and GR) in patients with AD and VD and significant differences were observed between CRT and AD patients for ages from 65 to 74, 75 to 84 and from 85 years to 94 years in SOD activity and MDA levels (P < 0.001). MDA levels increase with age in VD, AD and CTR. No significant variation with respect to sex were detected, but significant variations in MDA levels were detected between CRT and patients with VD and AD (P < 0.001). We conclude that oxidative stress plays an important role in the brain damage for both AD and VD, being observed higher levels of oxidative stress for AD that for VD.
Introduction
The main type of dementia and prototype for study of dementia is Alzheimer's disease (AD). AD is the most common degenerative disorders of the brain. Clinically AD is characterized by progressive memory loss, intellectual and emotional dysfunction, changes in neuroendocrine and autonomic functions [1, 2] . In developed countries, AD is tied with stroke as the 3rd leading cause of death. By age 80, almost 30% of the population will develop some type of dementia, with AD predominating. This disease affects individuals of all races and ethnic groups. Another common form of dementia is called vascular dementia (VD). This is often referred to as a dementia caused by ''ministrokes''. The risk factors for such dementia are similar to the risks of cardiovascular disease including family history, elevated lipids, diabetes mellitus, smoking and prior stroke [3] . VD is an increasing and often unrecognized health problem that currently may affect more than 1 million people in the USA [4] . As many as 25% of patients aged 65 and older may develop VD after ischemic stroke [4] .
The etiology of AD is complex and involves the formation of Amyloid beta (Ab) deposition into the brain which is considered a crucial step in AD development, as it originates a cascade of neuroinflammatory events leading to irreversible neuronal damage [5] . In particular, Ab and others lesion-associated proteins are a major source of reactive oxygen species (ROS) and others toxic radicals [6] .
It has been reported that oxidative stress may play a role in the pathogenesis of dementia of the Alzheimer type [7] and the cerebral ischemia [8] which causes VD, because the brain is particularly susceptible to free radical attack, because to it generates more of these toxicants per gram of tissue than any other organ does [9] . It is a highly oxygenated structure, responsible for almost one fifth of the body's total oxygen consumption. In addition, it contains large amounts of iron and polyunsatured fatty acids which make an excellent substrate for free radical reactions and is relatively poor in many antioxidants, such as catalase [9, 10] . The main damage to cells results from the free radical-induced alteration of macromolecules such as polyunsaturated fatty acids in membrane lipids, essential proteins, and DNA.
Lipid peroxidation, a general mechanism whereby free radicals induce tissue damage, has been implicated under diverse pathological conditions, including brain disorders. Lipid peroxidation is one of the major outcomes of free radical-mediated injury that directly damages membranes and generates a number of secondary products including aldehydes, such as malondialdehyde (MDA), and 4-hydroxy-2-nonenal, ketones, etc [11] . Free radicals exert their cytotoxic effect by peroxidation of membrane phospholipids, changing the permeability of cellular membrane, increasing their fluidity, their rigidity and in some cases making them lose their integrity and increasing the risk of membrane rupture. Malondialdehyde (MDA) is the most abundant individual aldehyde resulting from lipid peroxidation, subsequently, this aldehyde can be considered as a marker of the lipid peroxidation [12] . In this way, elevated levels of MDA are indicative of a high oxidative stress [13] .
The biological effects of these highly reactive compounds are controlled in vivo by a wide spectrum of antioxidative defense mechanisms such as vitamins E and C, carotenoids, metabolites such as uric acid or glutathione and antioxidants enzymes. Cells have developed an enzymatic antioxidant pathway against free radicals and reactive oxygen species (ROS) which are generated during oxidative metabolism: firstly, superoxide dismutase (SOD) catalyzes the formation of hydrogen peroxide from superoxide radicals. Hydrogen peroxide can generate toxic hydroxyl radicals, but it is removed by a reaction catalyzed by catalase (CAT) and glutathione peroxidase (GPx) [14] . Glutathione reductase is a flavoprotein catalyzing the NADPH-dependent reduction of glutathione disulfide (GSSG) to glutathione (GSH), which is essential for the maintenance of glutathione levels. Any increase in SOD catalytic activity produces an excess of hydrogen peroxide that must be efficiently neutralized by CAT or GPx. The activity of first and second step antioxidant enzymes must, therefore, be balanced to prevent oxidative damage in cells, which may contribute to various pathological processes [15] .
In this study, we measured MDA levels and SOD, CAT, GPx and glutathione reductase (GR) activities in blood samples from patients with AD and VD and in healthy nondemented controls (CTR) with similar ages to the patients, in order to evaluate the degree of oxidative stress in patients with AD and VD. The simultaneous measurement of all variables of the antioxidant activity and MDA levels provides information on their correlations allowing the comparison of pathological entities.
Material and methods

Patients
All subjects of the sample were resident in the same geographic area at the time of the study. We obtained consent for this study from the families of the patients; the measurements were performed without giving information to the AD and VD patients themselves and in the same way we obtained written informed consent from healthy volunteers.
This study, performed in accordance with the Ethical Standards outlined in the Declaration of Helsinki (1975) as revised in 1983 and 1996, was carried out in 150 subjects consisting of 50 patients (24 males, 26 females) with probable dementia of the Alzheimer type (AD); 50 patients (22 males, 28 females) with vascular dementia (VD) and 50 (23 males, 27 females) healthy controls (CTR). None of the subjects of this study were related. CTR subject were included by age and sex to reflect the general gender and age distribution of the diseased groups and without any form or pharmacologic treatment, negative history of cardiovascular, respiratory, hepatic or neurological diseases, diabetes mellitus, neoplasic syndrome, severe arthrosis or alcoholism and without pathological biochemistry and/or haematological parameters. We established 3 groups according to age: group I, aged from 65 years to 74 years; group II, aged from 75 years to 84 years and group III, aged from 85 years on.
Patients were included in the study according with accepted neurological criteria for each group: AD patients were diagnosed using the criteria of the NINCDS-ADRDA [16] and also included clinical history (Camdex), physical examination, neurochemistry parameters and neuroimaging procedures [17] . VD patients were diagnosed according to the NINDS-AIREN criteria [18] . Patients were excluded from the study if they were affected by diabetes mellitus, myeloproliferative disorders, uncontrolled hypertension, Blood sampling
Blood samples (5 ml), of patients and the control group, were taken using heparinized vacuum tubes (Venoject) from the cubital vein (right arm) and stored at 4°C. All assays were carried out with in 24 h of sampling.
Superoxide dismutase activity determination
The SOD activity was measured in red blood cell. 0.1 ml of blood was hemolyzed by 0.9 ml of ice cold water (0-4°C). The hemoglobin was removed by adding 0.25 ml of chloroform and 0.5 ml of ethanol followed by vigorous mixing. The mixture was centrifugated at 18,000 g for 60 min. The clear supernatant was used for superoxide dismutase assay. This assay was performed using the method of Minami and Yoshikawa [19] , which is based on the inhibition by SOD of the nitro blue tetrazolium reduction produced by superoxide radical generated by the autoxidation of pirogallol. The intensity of the superoxide reaction by SOD was calculated according to the definition of McCord and Fridovich [20] .
Catalase activity determination
The CAT activity was measured in hemolysates by the method of Aebi [21] . The hemoglobin solution was obtained from fresh red blood cells. Heparinized blood samples were centrifuged at 2,500 g for 10 min, and the plasma was then removed as completely as possible. The red cells were washed three times with 0.9% NaCl solution and subsequently hemolyzed by addition of distilled water.
The decomposition of the substrate, H 2 O 2 , was measured using a spectrophotometer at 240 nm. The activity was expressed as k-rate constant of the first order reaction as defined by Aebi [21] -per gram hemoglobin.
Glutathione peroxidase determination
The GPx activity was measured in hemolysates by the modified method of Paglia and Valentine [22] described by Carmagnol et al. [23] . Hemoglobin was converted to cyanmethemoglobin by reaction with potassium cyanide and potassium ferrycianide, to minimize its pseudoperoxidase reactivity. GPx activity was measured by a coupled assay system in which oxidation of GSH was coupled to NADPH oxidation catalyzed by glutathione reductase. The reaction mixture consisted of 0.25 mM cumene hydroperoxide, 1 mM GSH, 1.4 units of yeast glutathione reductase, 1.43 mM NADPH and 1.5 mM KCN in 100 mM potassium phosphate buffer (pH 7.00). GSSG produced by the action of GPx and peroxide was reduced by glutathione reductase and NADPH, the decrease in concentration of NADPH being recorded at 340 nm. About 1 unit of GPx activity was defined as the amount of enzyme that catalyzed the transformation of 1 nM of NADPH per minute. Enzyme activity was expressed as units per gram of hemoglobin.
Glutathione reductase determination
The GR activity was measured in hemolysates by the method of Calberg and Mannervik [24] . The oxidation of NADPH was followed spectrophotometrically at 340 nm.
The reaction mixture consisted of potassium phosphate buffer 0.2 M, pH 7.0, containing 2 mM EDTA, NADPH, 2 mM, in 10 mM Tris-HCl (pH 7.0), oxidized glutathione (GSSG), 20 mM, in water. To a 1 ml cuvette, 0.5 ml phosphate buffer, 50 ll NADPH, 50l GSSG, and a volume of deionized water giving a final total volume of 1 ml is added. The reaction is initiated by addition of enzyme to the cuvette and is followed by the decrease in absorbance at 340 nm. A unit of GR activity is defined as the amount of enzyme that catalyzes the reduction of 1 lmol of NADPH per minute. Enzyme activity was expressed as units per gram of hemoglobin.
Malondialdehyde determination MDA levels were measured in erythrocytes by the Bull and Marnett method [25] . Blood was centrifuged at 2,500 g for 10 min, and the plasma was then removed as completely as possible. Erythrocytes were washed three times with 0.9% NaCl solution and subsequently hemolized by addition of distilled water. The supernatant solution was diluted by addition of acetonitrile (v/v) followed by vigorous mixing. The mixture was centrifugated at 3,000 g for 5 min. The supernatant solution was filtered (0.2 lm pore-diameter membrane). High-pressure liquid chromatography (HPLC) was performed in a high-pressure liquid chromatograph (Pharmacia LKB Bromma model 2151 Sweden) equipped with a LKB Bromma 2151 model diode array UV detector and ChromJet integrator Spectra-Physics data processor (PEMED) Production Engineering-Medical Equipment Division (Denver, Colorado, USA), which enabled the peak purity to be analyzed. An ODS Hypersil column (25 cm · 4,6 mm, 5 lm) (Shandon Scientific Ltd, Runcorn, Cheshire, UK) was the stationary phase. The chromatographic conditions employed were mobile phase PO 4 HNa 2 and miristilammonium bromide buffer (pH 7.4)/acetonitrile. The flow rate was 0.4 ml/min; UV detection at 268 nm; the chart speed was 0.5 cm/min.; attenuation 6, and the temperature was ambient. Injection volumes were 10 ll.
The column was equilibrated at the beginning of each daily series of measurements with at least 50 ml of the eluant. The MDA peak in the chromatogram was identified by comparison with a reference chromatogram of freshly prepared free MDA. The concentration of MDA was calculated from the area, on the basis of a calibration chromatogram performed with a standard solution of MDA which was prepared by acid hydrolysis as described by Esterbauer et al. [26] .
Statistical analysis
Data were processed using standard statistical software such as SPSS 10.2 (SPSS Inc., Chicago, IL, USA). Results are expressed as mean ± standard deviation. The distribution of the groups was analyzed using the KolmogorovSmirnov test. As both groups showed a normal distribution, parametric statistical methods were used. For comparison of the groups, Student's ''t'' test and analysis of variance (ANOVA) were performed. To assess significant F-ratios obtained via analysis of variance, the Bonferroni post-hoc test was used. Differences were considered significant for P < 0.05. Table 1 shows the results obtained, expressed as mean ± standard deviation of SOD activity in the control group and patients with VD and AD stratified by age. Significant differences were observed between females and males of the control group (P < 0.001), this fact was observed in a Spanish population 50-93 years [27] . Significant differences were also observed between females and males in patients with AD (P < 0.02). Significant differences were observed between females of the control group and patients with VD (P < 0.005) and AD (P < 0.001) and between males of the control group and males of patients with AD (P < 0.05). Significant differences were also observed between the control group and the group of patients with AD for ages from 65 to 74, 75 to 84 and from 85 years on. In patients with VD we observed significant differences with respect to the control group only for ages from 85 years on.
Results
As can be seen in Table 2 (that shows the results obtained, expressed as mean ± standard deviation of CAT activity in the control group and patients with VD and AD stratified by age), in this work we did not observe any significant differences in CAT activity between the group of patients with VD and the control group, but significant i SOD = superoxide dismutase activity in units/ml of blood No = number; X ± SD = Mean ± Standard Deviation a significant differences between females and males in the control group (P < 0.001) b significant differences between females and males in patients with Alzheimer dementia (P < 0.02) c significant differences between females of the control group and females with vascular dementia (P < 0.005) d significant differences between females of the control group and females with Alzheimer dementia (P < 0.001) e significant differences between males of the control group and males with Alzheimer dementia (P < 0.05) f significant differences between the control group and patients with Alzheimer dementia aged 65-74 years (P < 0.02) g significant differences between the control group and patients with Alzheimer dementia aged 75-84 years (P < 0.005) h significant differences between the control group and patients with vascular dementia aged 85-94 years (P < 0.01) i significant differences between the control group and patients with Alzheimer dementia aged 85-94 years (P < 0.001) Neurochem Res (2008) 33:450-458 453 differences were found between the control group and the patients with AD for ages from 65 to 74. No significant variations with respect to sex were detected neither in the control group nor patients group. However, in previous work [28] we have detected significant differences between males and females for ages from 70 to 79, and from 80 years to 89 years. Table 3 shows the results obtained, expressed as mean ± standard deviation of GPx activity in the control group and patients with VD and AD stratified by age. Significant differences were observed between the control group and the group of patients with AD for ages from 65 to 74, and from 75 to 84. No significant variations with respect to sex were detected neither in the control group nor patients group. Table 4 shows the results obtained, expressed as mean ± standard deviation of GR activity in the control group and patients with VD and AD stratified by age. Significant differences were observed only between the control group and the group of patients with AD for ages from 75 to 84. With respect to sex in males we have detected more GR activity than females in the control group as well as patients group with significant differences for the control group (P < 0.001) and AD patients (P < 0.05). Table 5 shows the results obtained, expressed as mean ± standard deviation of MDA levels in the control group and patients with VD and AD stratified by age. Significant differences were observed between females of the control group and patients with VD (P < 0.001) and AD (P < 0.001). Significant differences were observed between males of the control group and patients with VD (P < 0.001) and AD (P < 0.001). Significant differences were also observed between the control group and the group of patients with VD and AD for ages from 65 to 74, and from 75 to 84. Significant differences were also observed between the control group and the group of patients with AD from 85 years on. No significant variations with respect to sex were detected neither in the control group nor patients group. CAT = catalase activity in k/g of hemoglobin No = number; X ± SD = Mean ± Standard Deviation a significant differences between the control group and patients with Alzheimer dementia aged 65-74 years (P < 0.02) 
Discussion
Several studies have demonstrated that reactive oxygen species (ROS) production in AD or VD is not restricted to the brain. Leutner el al. [29] have founded enhanced ROSgeneration in lymphocytes from Alzheimer's disease. An increase in markers of lipid peroxidation and a decrease in antioxidants have been detected by Rinaldi et al. [30] in plasma. Zafrilla et al. [31] reported, in blood, oxidative stress in Alzheimer patients in different stages of the disease.
In the present work we decided to examine the antioxidant enzyme activities in erythrocytes, because they are representative cells with regard to their physiological role, oxygen radicals and H 2 O 2 being continuously generated by the autoxidation of hemoglobin [32] .
SOD activity shows significant differences between males and females in the control group (4.87 ± 0.75 vs. 4.02 ± 0.71) and in patients with AD (3.83 ± 0.71 vs. 3.11 ± 0.73), but not in VD. Considering the greater longevity of females, this trend is not unexpected. It is interpreted as one of the greater longevity in females [27] . No = number; X ± SD = Mean ± Standard Deviation a significant differences between females and males in the control group (P < 0.001) b significant differences between females and males in patients with Alzheimer dementia (P < 0.05) c significant differences between the control group and patients with Alzheimer dementia aged 75-84 years (P < 0.005) i MDA = Malondialdehyde levels in nM MDA/mg of hemoglobin No = number; X ± SD = Mean ± Standard Deviation a significant differences between females of the control group and females of vascular dementia (P < 0.001) b significant differences between females of the control group and females of Alzheimer dementia (P < 0.001) c significant differences between males of the control group and males of vascular dementia (P < 0.001) d significant differences between males of the control group and males of Alzheimer dementia (P < 0.001) e significant differences between the control group and patients with vascular dementia aged 65-74 years (P < 0.001) f significant differences between the control group and patients with Alzheimer dementia aged 65-74 years (P < 0.001) g significant differences between the control group and patients with vascular dementia aged 75-84 years (P < 0.05) h significant differences between the control group and patients with Alzheimer dementia aged 75-84 years (P < 0.001) i significant differences between the control group and patients with Alzheimer dementia aged 85-94 years (P < 0.05) Some studies have reported that SOD activity to be increased in the erythrocytes [33, 34] , whereas other have founded SOD activity normal [35] , and other have found a decreased in SOD activity [36, 37] in patients with AD. In this study SOD activity in AD was significantly lower than in the control group. This is in accordance with the results obtained by Richardson, Chen et al., and Ihara et al. [36] [37] [38] . On the other hand, it has been reported that SOD activity is increased in the erythrocytes of patients with VD [34] , but in the present study SOD activity was lower than in the control group, however the differences were not statistically significant. Similar results were obtained in patients with VD by Ihara et al. [38] . CAT activity was least affected because the brain is relatively poor in many antioxidants such as catalase and shows no significant differences between males and females neither control group or patients with VD or AD. CAT activity is lower in patients with VD and AD, but statistically significant differences were only found between the control group and patients with AD for the group of 65-74 years (219 ± 13 vs. 203 ± 10). De la Torre et al. [35] had reported a decreased CAT activity in patients with AD as well as Venarucci et al. [39] in dementias while Perrin et al. [33] reported an increase in this activity.
GPx activity shows no significant differences between males and females neither in the control group or in patients with VD or AD. Serra et al. [40] also obtained no association between sex and antioxidant profiles in demented (dementia type Alzheimer and vascular dementia) patients. GPx activity is lower in patients with VD and AD, but statistically significant differences had only been found between control group and patients with AD for groups of 65-74 and 75-84 years (P < 0.005). This is in accordance with results obtained by Jeandel et al. [41] who obtained a significant decrease of GPx activity in patients with AD contrary to the study of Anneren et al. [42] .
GR activity shows statistically significant differences between males and females of the control group (2.53 ± 0.43 vs. 1.94 ± 0.36) and patients with AD (1.95 ± 0.34 vs. 1.61 ± 0.37). GR activity is lower in patients with VD and AD but, statistically significant differences were only found between control group and patients with AD for ages from 75 to 84 (2.59 ± 0.32 vs. 1.98 ± 0.37).
Foy et al. [43] have also observed significant reductions in antioxidants (vitamin A, vitamin C, beta-carotene) in dementia groups (vascular dementia and Alzheimer disease) when they are compared to the controls. Guidi et al. [44] have also observed decreased in total antioxidant activity mean values in patients with AD, but no in patients with VD supporting the hypothesis that oxidative status may be specifically altered in AD but not in other neurodegenerative diseases [45] such as VD. On the other hand, although defenses against damage produced by ROS are extensive, including enzymatic and small molecule antioxidant as well as repair enzymes, an increased production of ROS or a poor antioxidant defense network can lead to a progressive damage in the cell with a decline in physiological function [46] . Research suggests that treatments that reduce oxidative stress or cholesterol through exercise, diet or the use of antioxidant vitamins may delay cognitive decline [47] . Moreover, the intake of antioxidant vitamins, particularly vitamin E or the combination of vitamin E and vitamin C (ascorbic acid), reduced the risk of Alzheimer's disease [48, 49] .
Lipid peroxidation is one of the major outcomes of free radical-mediated injury that directly damages membranes and generates a number of secondary products, both from fission and endocyclization of oxygenated fatty acids that possess neurotoxic activities. Lipid peroxidation is a central feature of oxidative stress and can be assessed by a number of methods including the quantification of peroxidation end products. MDA is one of the end products of lipid peroxidation and extent of lipid peroxidation is most frequently measured by estimating MDA levels. Numerous studies have demonstrated increased lipid peroxidation in brain of patients with AD compared with age-matched controls. MDA levels in the present study showed a statistically significant difference between the control group and AD patients (P < 0.001) for all age groups and between control group and VD for individuals aged 65-74 and 75-84 years. MDA levels were highest in AD (897 ± 84) and in VA (712 ± 81) that in the control group (536 ± 78). This is in accordance with the results obtained by Bermejo et al. [50] in AD patients. Furthermore, in this study we have observed that MDA levels increase with age, which is in accordance to the results obtained by Gil et al. [51] in a Spanish population. Beside, Zafrilla et al. [31] have observed that lipid peroxidation was higher in Alzheimer patients in the advanced stage of the disease than in the control group.
The discrepancies observed in the different studies on AD and VD may be due to several factors. Sample size may be a critical aspect in determining the statistical significance of the differences observed. Moreover, differences may be partially due to different assays used. Another explanation of the discrepancies obtained by different studies on age, antioxidant enzymes and MDA levels might be related to the role played by genetic background or dietary habits, rendering difficult the disentangling of their influence from enzyme expression and activity [52] .
Conclusions
In this study we found that oxidative stress plays an important role in the brain damage for both AD and VD being observed higher levels of oxidative stress for AD that for VD. This oxidative stress could be caused by decrease in the activity of antioxidant enzymes, together with an increase in lipid peroxidation with high MDA levels.
